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Abstract  
 Background: Preoperative risk stratification is essential in tailoring endometrial 
cancer treatment, and biomarkers predicting lymph node metastasis and aggressive 
disease are aspired in clinical practice. DNA ploidy assessment in hysterectomy 
specimens is a well-established prognostic marker. DNA ploidy assessment in 
preoperative curettage specimens is less studied, and in particular in relation to the 
occurrence of lymph node metastasis. 
Methods: Curettage image cytometry DNA ploidy in relation to established 
clinicopathological variables and outcome was investigated in 785 endometrial 
carcinoma patients prospectively included in the MoMaTEC multicentre trial. 
 Results: Diploid curettage status was found in 72.0%, while 28.0% were non-
diploid. Non-diploid status significantly correlated with traditional aggressive 
postoperative clinicopathological features, and was an independent predictor of lymph 
node metastasis among FIGO stage I-III patients in multivariate analysis (OR=1.94, 
p=0.033). Non-diploid status was related to shorter disease-specific survival (5-year DSS 
of 74.4%, vs. 88.8% for diploid curettage, p<0.001). When stratifying by FIGO stage and 
lymph node status, the prognostic effect remained. However, in multivariate regression 
analysis, preoperative histological risk classification was a stronger predictor of disease-
specific survival than DNA ploidy. 
 Conclusion: Non-diploid curettage is significantly associated with aggressive 
clinicopathological phenotype, lymph node metastasis and poor survival in endometrial 
cancer. The prognostic effect was also observed among subgroups with (presumably) 
less aggressive traits, such as low FIGO stage and negative lymph node status. Our 
results indicate curettage DNA ploidy as a possible supplement to existing parameters 
used to tailor surgical treatment. 
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Introduction 
Endometrial carcinoma is the most common gynaecological malignancy in the 
western world with a reported lifetime risk of 2-3% (Jemal et al, 2010). In Norway, it 
constitutes 6% of all female cancers. A steady increase in incidence over the last decades 
has been observed (Cancer Registry of Norway, 2012), attributed to an ageing 
population and increasing incidence of obesity (Sorosky, 2012). In the United States, 
estimates by The American Cancer Society predict 52,630 new cases and 8,590 
endometrial cancer deaths in 2014 (American Cancer Society, 2014; Siegel et al, 2014).  
Abnormal uterine bleeding is the cardinal symptom of endometrial cancer. 
Essential preoperative diagnostic work-up includes histological verification by 
endometrial biopsy or curettage, in combination with a selection of imaging techniques 
to predict metastatic disease. Surgery remains the cornerstone in primary treatment; 
with curative intent it includes total hysterectomy and bilateral salpingo-oophorectomy, 
with or without retroperitoneal lymph node dissection and omentectomy, dependent on 
risk assessment based on tumour characteristics as well as patient operability (Amant et 
al, 2005).  
Prognostic factors in endometrial cancer have been thoroughly investigated, the 
most important being age, the surgical FIGO stage (International Federation of 
Gynecology and Obstetrics), myometrial invasion, histological subtype and grade, and 
lymphovascular invasion (Amant et al, 2005; Creutzberg et al, 2000; Prat, 2004), serving 
as important determinants of tailoring postoperative treatment. Fortunately, the 
majority of endometrial cancer patients are diagnosed at a relatively early stage with 
disease presumably confined to the uterus. This is reflected by a generally favourable 
prognosis, with a 5-year relative survival of 84.4% reported for the period 2008-2010 in 
Norway (Cancer Registry of Norway, 2012), and 5-year disease-specific survival 
reported to 86.9% (Trovik et al, 2012). However, endometrial carcinoma is a 
heterogeneous disease with great variations in aggressiveness, exemplified by a 
recurrence rate after primary surgery among patients with presumed localized disease 
of 15-20% (Abeler & Kjorstad, 1991). Consequently, much effort has been made to 
individualize treatment by (preferably preoperatively) more accurately identifying 
patients with higher risk for poor outcome requiring more aggressive treatment, as well 
as identifying low-risk patients to avoid overtreatment (Salvesen et al, 2012). As 
reviewed by Salvesen et al, today’s preoperative risk assessment based on endometrial 
histology and imaging could be further augmented by preoperatively accessible 
biomarkers, such as curettage specimen hormone receptor status (Trovik et al, 2013), 
stathmin expression (Trovik et al, 2011) and DNA ploidy (Fredstorp-Lidebring et al, 
2001; Mariani et al, 2000; Pradhan et al, 2012; Steinbakk et al, 2011) for tailored 
surgical treatment.  
Assessment of DNA ploidy status has been shown to be of prognostic value in 
several epithelial cancers (Merkel & McGuire, 1990). For endometrial cancer patients, 
DNA ploidy postoperatively acquired from hysterectomy specimens has repeatedly been 
reported to be of prognostic importance, with aneuploidy or non-diploidy as a marker 
for aggressive disease (Larson et al, 1999; Lundgren et al, 2004; Pfisterer et al, 1995; 
Pradhan et al, 2012; Salvesen & Akslen, 2002; Susini et al, 2007; Wik et al, 2009; Zaino et 
al, 1998). However, only few studies have assessed the value of DNA ploidy in 
preoperatively available curettage specimens, both in terms of prognosis (Fredstorp-
Lidebring et al, 2001; Mariani et al, 2000; Pradhan et al, 2012; Steinbakk et al, 2011) and 
in relation to lymph node status (Mariani et al, 2005). As results from multivariate 
analysis are conflicting (Mauland et al, 2014; Terada, 2012), the clinical value of DNA 
ploidy assessment needs further validation. 
On this background, we have investigated DNA ploidy in curettage specimens in 
relation to a panel of clinicopathological variables, lymph node status and outcome for 
women diagnosed and treated for endometrial cancer in the prospective, international 
multicentre trial MoMaTEC1 (Molecular Markers in Treatment of Endometrial Cancer).  
 
Materials and methods 
Study cohort 
With Regional Ethics Committee approval, a total of 1046 consenting patients in 
the MoMaTEC1-trial  (Molecular Markers in Treatment of Endometrial Cancer, Clinical 
Trial identifier NCT00598845) were included in this study. The study has acquired 
approval of The Norwegian Data Inspectorate (961478-2), Norwegian Social Sciences 
Data services (15501), and Regional Committees for Medical and Health Research Ethics 
(REKIII no. 052.01). A total of 402 endometrial cancer patients were prospectively 
included when treated at the Department of Gynaecology and Obstetrics, Haukeland 
University Hospital, Bergen, Norway, from May 2001 through March 2011. Nine other 
centres contributed with 644 patients treated for endometrial carcinoma prospectively 
included at their institutions. Sampling was performed by pipelle or dilatation and 
curettage as per routine for each contributing centre. Formalin-fixed paraffin-embedded 
tumour tissue from curettage specimens was collected from all participating institutions.  
Clinicopathological data, including age at diagnosis, FIGO stage according to 2009 
criteria, histology (type and grade) from hysterectomy specimens, and treatment 
modalities were recorded. Preoperative curettage histology reports were routinely 
categorized as either high-risk (standardly comprising histological type reported as non-
endometrioid, or histological grade 3 endometrioid carcinoma) or low-risk (standardly 
comprising other histological diagnoses including grade 1 or 2 endometrioid carcinoma, 
hyperplasia, and benign endometrium). All precision samples selected for DNA ploidy 
analysis as later described were investigated for presence of malignant tissue by one of 
the co-authors (MP), irrespectively of the preoperative routine histological diagnosis. 
Complying with the aim to evaluate DNA ploidy impact in a patient group treated 
routinely in a prospective multicentre setting, routine histological reports for grading 
and subtyping were applied from the participating centres. Follow-up data with records 
of recurrence and survival was collected from patient records and correspondence with 
physicians responsible for outpatient controls. 
 
DNA ploidy analyses 
 Haematoxylin and eosin stained slides from individual curettage specimen were 
evaluated to identify tissue areas with highest tumour grade. From the selected area, 
one or two 1 mm cylinders were punched out using a custom made precision instrument 
(Beecher Instruments) depending on the curettage tissue depth. Prepared monolayers 
were stained with Feulgen-Schiff as previously described by (Pradhan et al, 2006). The 
nuclear DNA content was measured using the Ploidy Work Station (PWS) Grabber 
version 1.4.12 (Room 4 ltd, UK) and a Zeiss Axioplan microscope equipped with a 546-
nm green filter and a black and white high-resolution digital camera (Axiocam MRM, 
Zeiss). DNA ploidy histograms were created based on Integrated Optical Density of the 
nuclei using PWS Classifier (vs 3.06.03, Room 4 ltd, UK). DNA ploidy histograms were 
classified as diploid (one G0/G1 peak and G2 less than 10%), aneuploid (DNA Index (DI) 
1.06-1.89, 2.11-3.79 or >4.2), tetraploid (DI 1.90-2.10) or polyploid (DI 3.8-4.2). A 
detailed description of the procedure, DNA content measurement, and histogram 
classification criteria is given elsewhere (Pradhan et al, 2006). Samples with less than 
200 nuclei, and samples with poor technical quality were not classified. 
 
Statistical analysis 
 For statistical analysis, SPSS, Statistical Package for the Social Sciences, version 
20.0 (IBM, Chicago, IL, USA) was applied. Associations between categorical variables 
were explored using Pearson’s chi-square test, and odds ratios (OR) for lymph node 
metastasis by binary logistic regression. For evaluation of prognostic impact, disease-
specific survival (DSS) was defined as time from surgery until death from endometrial 
carcinoma, as documented from each patient’s responsible clinician. Univariate survival 
analyses were conducted by the Kaplan-Meier method with log-rank test for statistical 
significance, and multivariate survival analyses by Cox regression. All tests were two-
sided, and results were considered statistically significant with a probability of less than 
0.05. 
 
Results 
Of 1046 curettage samples, 236 samples were discarded due to lack of sufficient 
tissue material, being not measurable, or unclassifiable due to poor technical quality. 
Additional 25 patients had incomplete clinicopathological data upon study completion, 
leaving 785 patients for the final analysis. Follow-up information was available for 733 
patients, with a mean follow-up among survivors of 38.4 months (range 0-96 months).   
Of these 785 patients, 97.2% (n=763) were treated with primary hysterectomy 
and bilateral salpingo-oopherectomy, including lymph-node staging in 74.4% of the 
cases (n=584), 2.4% (n=19) were treated by curettage only, and 0.4% (n=3) by 
cytoreductive surgery. Lymph node sampling was predominantly pelvic, but included 
para-aortic dissection for a minority of patients (n=27). Performed lymph node 
dissection was significantly associated with younger age (82.6% of patients under 66 
years vs. 66.5% of patients over 66 years, p<0.001), but showed no significant 
association to preoperative histological risk classification or curettage DNA ploidy 
(Supplementary table 1). Additionally, 33.6% of the patients (n=264) received adjuvant 
therapy, consisting of various combinations of radiation (n=115), hormonal treatment 
(n=13) and/or chemotherapy (n=171). The study complied with standardly applied 
treatment protocols for adjuvant therapy at the including centre, individually adjusted 
for each patient by the responsible physicians. Hormonal treatment was given to 13 
patients due to high age (median 86 years) and/or inoperability. None of the patients 
had a prior history of endometrial cancer, and none received neoadjuvant radiation or 
chemotherapy.  
Evaluating DNA ploidy from curettage samples, 72.0% (n=565) were classified as 
diploid, 20.6% (n=162) as aneuploid, 6.6% (n=52) as tetraploid and 0.8% (n=6) as 
polyploid. Dichotomizing patients according to diploid and non-diploid curettage 
specimens, aneuploid, tetraploid and polyploidy tumours were merged, constituting 
28.0% of total patients included. Details for clinicopathological and demographic 
characteristics of the study cohort are presented in Table 1. Distribution of preoperative 
and postoperatively available clinicopathological findings in relation to DNA ploidy 
status are presented in Table 2. Non-diploid curettage specimen was significantly 
associated with high FIGO stage, non-endometrioid histological subtype in hysterectomy 
specimen, high histological grade in hysterectomy specimen, and high-risk curettage 
classification (all p<0.001). Associations between lymph node status, clinicopathological 
variables and DNA ploidy are presented in Table 3. Interestingly, patients with non-
diploid curettage had significantly higher occurrence of lymph node metastasis 
compared to patients with diploid curettage (20.6% vs. 9.1% respectively, p<0.001). 
High-risk curettage classification was also associated with lymph node metastasis 
compared to low-risk curettage (24.8% vs. 8.6% respectively, p<0.001), in concordance 
with previously established research findings and clinical practice for identifying high-
risk patients for more extensive lymphadenectomy. 
Biopsy reports were routinely categorized as either low- or high-risk for clinical 
risk stratification, as previously described (Trovik et al, 2011). Among patients with 
FIGO stage I-III, non-diploid curettage specimens significantly predicted the occurrence 
of lymph node metastasis both in univariate analysis (OR 2.73, 95% CI: 1.60-4.66, 
p<0.001) and in multivariate analysis when adjusted for reported preoperative 
curettage risk stratification (OR 1.94, 95% CI: 1.06-3.55, p=0.033)(Table 4). However, 
the long established high-risk histology classification had a similar association to 
positive lymph node status (OR 2.23, 95% CI: 1.20-4.13, p=0.011)(Table 4).  
In univariate survival analysis, results from surgical staging incorporating final 
histpoathological diagnosis, FIGO stage, depth of myometrial infiltration, and lymph 
node status were, as expected, statistically significant predictors of disease-specific 
survival (DSS) (Table 5). Among preoperatively available information, age, DNA ploidy 
and histological risk classification showed significant associations. Patients with non-
diploid curettage specimens had significantly shorter 5-year DSS compared to patients 
with diploid curettage (74.4% compared to 89.6% 5-year DSS, p<0.001) (Fig. 1A). A 
similar pattern was found when analysing FIGO stage I and II patients in isolation, with a 
5-year DSS of 95.4% for diploid curettage, versus 86.3% for non-diploid curettage 
(p<0.001) (Supplementary table 2 and Fig. 1B). Noticeably, when viewing the subgroup 
of women with high FIGO stage (III and IV), no significant difference in ploidy-
dependent survival was observed, with 5-year DSS for diploid and non-diploid curettage 
of 41.4% and 38.1% respectively (p=0.267).  
 Subgroup analysis was also performed according to lymph node status 
(Supplementary table 2). Comparing ploidy status isolated to patients with positive 
lymph node status (n=66), negative lymph node status (n=485) or unevaluated lymph 
node status (n=182), a significant reduction in 5-year DSS for non-diploid status was 
observed among the two latter. Five-year survival proportions for diploid vs. non-
diploid curettages were 59.0% vs. 55.2% for patients with positive lymph node status 
(Fig. 2A, p=0.680), 95.5% vs. 88.3% for patients with negative lymph node status 
(p=0.003, Fig. 2B), and 80.5% vs. 47.2% for patients with unevaluated lymph node 
status (p<0.001, Fig. 2C). Furthermore, considering patients with FIGO stage I/II only 
and concomitant unevaluated lymph node status only, the prognostic effect of non-
diploid status remained. Among lymph node unevaluated patients with localized disease, 
the survival proportions were significantly lower for patients with non-diploid versus 
diploid curettage, with 5-year DSS of 93.4% and 62.0% respectively (Fig. 2D, p=0.001). 
 Results from multivariate Cox regression analyses are listed in Supplementary 
table 3. Unadjusted for other parameters, non-diploid curettage was associated with a 
significant increase in risk of disease-specific death among FIGO stage I-III patients 
(unadjusted HR of 3.63, p<0.001). When adjusting for preoperatively available curettage 
risk classification, non-diploid curettage status did not remain significant, but showed a 
62% increased risk of disease-related death (HR 1.62, 95% CI: 0.90-2.92, p=0.111). 
Discussion 
In endometrial carcinoma, DNA ploidy from hysterectomy specimens has 
repeatedly been reported to be of prognostic importance, with either aneuploid or non-
diploid tumours associating with more aggressive phenotype (Larson et al, 1999; 
Lundgren et al, 2004; Pfisterer et al, 1995; Pradhan et al, 2012; Salvesen & Akslen, 2002; 
Susini et al, 2007; Wik et al, 2009; Zaino et al, 1998). However, results from multivariate 
analysis are conflicting (Mauland et al, 2014; Terada, 2012), where some studies 
demonstrate an independent effect on survival (Lundgren et al, 2004; Susini et al, 2007; 
Zaino et al, 1998), while others do not (Larson et al, 1999; Pfisterer et al, 1995). One 
prospective implementation study has shown an independent prognostic effect in a 
routine diagnostic setting (Wik et al, 2009). Furthermore, the vast majority of studies 
are performed on hysterectomy specimens, and only a few studies have assessed the 
value of DNA ploidy in curettage samples as a predictor of poor outcome (Fredstorp-
Lidebring et al, 2001; Mariani et al, 2000; Pradhan et al, 2012; Steinbakk et al, 2011), or 
the relationship to lymph node status (Mariani et al, 2005). Of these, only one shows 
DNA ploidy in curettage specimens to be an independent prognostic factor, however 
results should be interpreted with care as DNA ploidy was only bivariately corrected for 
u-PA (urokinase plasminogen activator) or PAI-1 (plasminogen activator inhibitor type 
1) (Fredstorp-Lidebring et al, 2001). Furthermore, a study exploring DNA ploidy and 
lymph node status for 82 endometrial cancer patients found no significant association 
(Mariani et al, 2005). Our study is thus an important supplement to this inconclusive 
exploration of the significance of curettage DNA ploidy status.  
Noticeably, although the prognostic value of DNA ploidy in curettage specimens 
perhaps may be disregarded as inferior to hysterectomy samples, the strength of being 
preoperatively accessible before hysterectomy bears an immediate advantage as a 
possible supplement to preoperative risk assessment and prediction of lymph node 
metastasis. In this regard, our perhaps most important findings are that, among our 
patient cohort without distant metastasis at diagnosis, DNA ploidy is an independent 
predictor of lymph node metastasis, corrected for routinely performed curettage 
histological risk stratification (OR 1.94, p=0.033). For this analysis we excluded cases 
with FIGO stage IV metastatic disease, as their distant metastasis can be detected during 
preoperative work-up, and as they have poor prognosis and are subjected to highly 
individualized treatment strategies also dependent on comorbidity. FIGO stage II and III 
cases were included to avoid selection bias due to postoperative upstaging in a 
population with a high proportion of patients subjected to staging lymphadenectomy. 
Curettage risk stratification showed a stronger trend towards positive lymph node 
status (OR 2.23, p=0.011), although it may be considered a more subjective parameter. 
In this regard, contemplating DNA ploidy and histological risk stratification with other 
curettage biomarkers such as p53 and hormonal receptor status would be of interest, in 
particular since the latter methods are more applicable in a routine diagnostic setting. In 
our subgroup analysis portrayed in Supplementary table 2, we illustrate that DNA ploidy 
could be of use in a subset of patients to prognosticate disease behaviour, such as 
patients with unevaluated lymph node status. Noticeably, DNA ploidy was not 
significantly associated with disease-specific survival for patients with aggressive 
phenotype such as high FIGO stage and confirmed positive lymph node status. However, 
for patients with a presumably less aggressive disease such as low FIGO stage or 
negative lymph node status, patients with non-diploid tumours had significantly shorter 
disease-specific survival. The observation among patients not subjected to 
lymphadenectomy, where non-diploid curettage status was associated with shorter 
disease-specific survival, supports a particular relevance for DNA ploidy assessment 
among patients with unevaluated lymph node status. Our findings could be confounded 
by patient operability; however, excluding patients with high FIGO stage did not alter 
the significance of our results (Fig 2D). Our data suggest that DNA ploidy evaluated in 
curettage specimens can represent an important clinical tool in risk stratification 
compared to surgical lymph node staging with documented short and long-term side 
effects (Amant et al, 2005; Salvesen et al, 2012). 
As noted, evaluation of DNA ploidy in postoperatively acquired hysterectomy 
samples may be viewed as superior to curettage specimens. This was exemplified in a 
comprehensive study by Pradhan et al. including patients with stage I and II 
endometrioid adenocarcinoma, concluding that analysis of hysterectomy specimen 
exceeded curettage specimens in predicting biological behaviour (Pradhan et al, 2010). 
As a possible explanation they postulate that the biology of the deep infiltrating parts of 
the tumour, of which samples are obtained after hysterectomy, are more important for 
recurrence development than the superficial part of the tumour, obtained by curettage. 
As a consequence of intratumoural heterogeneity, DNA ploidy classification may differ 
between hysterectomy and curettage specimens, as illustrated in a study comparing the 
two modalities (Pradhan et al, 2010). In an extensive study exploring the genomic 
landscape of primary renal cell carcinoma, Gerlinger et al conclude that the 
intratumoural heterogeneity undetected by single-tumour biopsy samples may present 
major challenges to personalized-medicine and biomarker development (Gerlinger et al, 
2012). This also directly applies to endometrial cancer, where any curettage sample 
evidently is restricted to not only represent a distinct area of the endometrium, but also 
a limited fraction of a tumour with potentially heterogeneous characteristics. This is an 
aspect that must be taken into consideration when implementing curettage biomarkers 
into clinical practice, including the reproducibility challenges faced with the standardly 
applied histological typing and grading (Salvesen et al, 2012). On the other hand, DNA 
ploidy may in this regard be characterized as a robust method taking intratumoural 
heterogeneity into account compared to other molecular markers, as a large amount of 
cell nuclei are measured with a high sensitivity of detecting subgroup aberrations. 
Tumour aneuploidy is a common genetic aberration in cancer reflecting a trait of 
genetic instability. Whether this aneuploidization is a cause or consequence of 
malignant transformation is uncertain (Holland & Cleveland, 2009). As opposed to 
structural chromosome rearrangements such as deletions, amplifications, or 
translocations, the role of whole-chromosome aneuploidy in cancer has received less 
attention (Gordon et al, 2012; Pellman, 2007). Aneuploidy has long been hypothesized 
as a promoter of tumourigenesis (Boveri, 1914). However, recent papers have shed light 
on the potential activation of oncogenes and inactivation of tumour suppressor genes 
leading to aneuploidy (Solomon et al, 2011), suggesting aneuploidy as a passenger of 
tumourigenesis. Aneuploidy is no obligatory trait of cancer, nor is cancer an obligatory 
consequence of aneuploidy. In concordance with other genetic instability, the pathways 
involved and the genetic context is of importance in developing the cancerous 
phenotype. The challenge remains to identify such genetic fingerprints, and translating 
results to individualize treatment, optimizing patient outcome. 
Our study is not without limitations. As noted, of the 1046 patients selected for 
DNA ploidy analysis, only 810 were successfully ploidy classified due to aforementioned 
reasons. This exclusion of 236 patients could cause a potential selection bias affecting 
our results. However, testing patients excluded from the study in terms of 
clinicopathological characteristics displayed in Table 1, no significant difference was 
observed in comparison to our final study cohort (all p>0.05, results not shown). 
Additionally, the proportion of patients unamenable for classification can limit the value 
of DNA ploidy assessment in routine use, calling for a method with higher rate of 
successful classification. Our approach of obtaining DNA ploidy material by punching 
out areas with highest tumour grade may pose a selection bias towards enriching for the 
more aggressive regions of the tumour in case of heterogeneity. However, this method 
allows small samples to be analysed, applicable to small endometrial biopsies. Our study 
cohort portrays a proportion of patients subjected to lymphadenectomy of 74.4%, 
illustrating a challenge complying with a staging procedure including lymphadenectomy 
in an elderly and often comorbid patient population. The extent of lymph node 
dissection was decided by the responsible surgeon, balancing patient comorbidity and 
risk involved in extended surgery. As expected, patients subjected to lymphadenectomy 
were significantly younger, while no other systematic biases were observed 
(Supplementary table 1). This suggests a selection bias of patients subjected to lymph 
node sampling based on age, but not the other investigated biomarkers.  
In conclusion, our study demonstrates that non-diploid curettage samples are 
associated with aggressive phenotype, lymph node metastasis and poor disease-specific 
survival. With the significant association between DNA ploidy and lymph node status, 
DNA ploidy can be of interest preoperatively to identify high-risk patients for tailored 
surgical treatment. Furthermore, subgroups of patients with presumably less aggressive 
traits, such as low FIGO stage and negative lymph-node status from staging 
lymphadenectomy, have significantly shorter disease-specific survival in the case of 
non-diploid curettage sample. This prognostic effect was also observed among patients 
not subjected to staging lymphadenectomy. Our results indicate DNA ploidy as a 
possible supplement to existing parameters used to tailor surgical treatment such as 
curettage histological risk stratification. However, additional studies, and in particular a 
prospective randomized clinical trial, would be important to evaluate the effect of 
implementing DNA ploidy into routine clinical practice. 
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Titles and legends to figures 
 
Fig. 1: Disease-specific survival (DSS) for endometrial cancer patients related to 
curettage specimens classified according to DNA ploidy. A) DSS for all patients, 
grouped according to DNA ploidy (n=733). B) DSS for patients with FIGO stage 
I/II according to curettage DNA ploidy (n=623). Patients with aneuploid, 
tetraploid and polyploid tumors were merged due to similar survival, and 
classified as non-diploid. The number of cases followed by the number of 
endometrial carcinoma related deaths is given in parenthesis. P-values are by 
Kaplan-Meier estimation by the log-rank test.  
 
Fig. 2: Disease-specific survival (DSS) for endometrial cancer patients in relation 
to curettage specimen DNA ploidy and lymph node status. A) DSS for patients 
with positive lymph-node status (n=66); B) DSS for patients with negative lymph 
node status (n=485); C) DSS for patients with unevaluated lymph node status 
(n=182); D) DSS for patients with FIGO stage I/II and unevaluated lymph node 
status (n=152). Patients with aneuploid, tetraploid and polyploid tumors were 
merged due to similar survival, and classified as non-diploid. The number of 
cases followed by the number of endometrial carcinoma related deaths is given 
in parenthesis. All p-values are by Kaplan-Meier estimation by the log-rank test.  
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Table 1. Clinicopathological and demographic characteristics for 785 endometrial cancer 
MoMaTEC* trial patients. 
 
Characteristics Mean SD, min-max 
Age (years)  66.4 11.1, 28-98 
Paritya  2.2  1.4, 0-8 
   
Characteristics Number of cases Percentage 
Information available preoperatively   
Curettage DNA ploidy   
Diploid 565 72.0 
Aneuploid 162 20.6 
Tetraploid 52 6.6 
Polyploid 6 0.8 
   
Information available postoperatively   
Histological subtypeb    
Endometrioid carcinomac 656 83.8 
Serous carcinoma 56 7.2 
Clear cell carcinoma 31 4.0 
Carcinosarcoma 27 3.4 
Undifferentiated carcinoma/other 13 1.7 
   
Histological differentiationd   
Grade 1 281 36.0 
Grade 2 272 34.9 
Grade 3 227 29.1 
   
Myometrial invasione     
<50% 453 64.0 
≥50% 255 36.0 
   
FIGO stage (2009 revision)   
I 608 77.5 
II 58 7.4 
III 91 11.6 
IV 28 3.6 
   
Lymph node metastasisf     
No 512 87.7 
Yes 72 12.3 
   
 
SD: Standard Deviation. aParity information missing for 10 patients. bHistological subtype 
missing for 2 patients.  cIncluding cases with squamous differentiation. dHistological 
differentiation missing for 5 patients. eData for myometrial infiltration not available for 77 
patients. fLymph node status evaluated in 584 patients. *Molecular Markers in Treatment of 
Endometrial Cancer 
Table 2. Clinicopathological variables related to DNA ploidy in curettage specimens from 785 patients with endometrial cancer, classified as 
either diploid or non-diploid (aneuploid, tetraploid and polyploid). All p-values are by Pearson chi-square test.  
 
Variables Category Diploid Non-diploid P-value 
Age at primary treatment < 66 years 309 80.3% 76 19.7%  
 ≥ 66 years 256 64.0% 144 36.0% <0.001 
       
Information available preoperatively       
Curettage histology classificationa Low risk 499 83.2% 101 16.8%  
 High risk 63 35.0% 117 65.0% <0.001 
       
Information available postoperatively       
FIGO stage (2009) I / II 503 75.5% 163 24.5%  
 III / IV 62 52.1% 57 47.9% <0.001 
       
Histological subtypeb Endometrioid 530 80.8% 126 19.2%  
(Hysterectomy specimen) Non-endometrioid 35 27.6% 92 72.4% <0.001 
        
Histological gradec Grades 1 and 2  462 83.5% 91 16.5%  
(Hysterectomy specimen) Grade 3 101 44.5% 126 55.5% <0.001 
       
Myometrial infiltrationd < 50% 349 77.0% 104 23.0%  
(Hysterectomy specimen) ≥ 50% 173 67.8% 82 32.2% 0.008 
       
Lymph node metastasise No 381 74.4% 131 25.6%  
 Yes 38 52.8% 34 47.2% <0.001 
       
Recurrencef No 443 76.5% 136 23.5%  
 Yes 58 57.4% 43 42.6% <0.001 
       
aCurettage histological risk classification as either low risk (benign, hyperplasia or endometrioid grade 1-2) or high risk (comprising non-
endometrioid or endometrioid grade 3 histology). Curettage histology risk classification missing for 5 patients. bHistological subtype missing for 
2 patients. cHistological grade missing for 5 patients. dMyometrial infiltration not available for 77 patients. eLymph node status evaluated in 584 
patients. fRecurrence only evaluated in patients considered tumour-free after operation (n=680). 
Table 3. Lymph node status in 584 endometrial cancer patients subjected to lymphadenectomy in relation to clinicopathological variables and 
expression of biomarkers. All p-values by Pearson’s chi-square test. 
 
Variable Category Lymph node negative Lymph node positive P-value 
       
Age < 66 years 279 87.7% 39 12.3%  
 ≥ 66 years 233 87.6% 33 12.4% 0.959 
       
Information available preoperatively      
Curettage histology classificationa Low risk 406 91.4% 38 8.6%  
 High risk 103 75.2% 34 24.8% <0.001 
       
Curettage DNA ploidyb Diploid 381 90.9% 38 9.1%  
 Non-diploid 131 79.4% 34 20.6% <0.001 
       
Information available postoperatively      
Histological subtypec Endometrioid 446 91.8% 40 8.2%  
(Hysterectomy specimen) Non-endometrioid 64 66.7% 32 33.3% <0.001 
        
Histological gradec Grades 1 and 2  384 93.0% 29 7.0%  
(Hysterectomy specimen) Grade 3 127 75.1% 42 24.9% <0.001 
       
Myometrial infiltrationd < 50% 334 97.7% 8 2.3%  
(Hysterectomy specimen) ≥ 50% 157 79.7% 40 20.3% <0.001 
       
 
aCurettage histological risk classification as either Low risk (benign, hyperplasia or endometrioid grade 1-2) or High risk (comprising non-
endometrioid or endometrioid grade 3 histology). bNon-diploid comprising aneuploidy, tetraploid and polyploidy curettage. cHistological subtype 
and grade missing for 2 patients. dMyometrial infiltration available for 539 patients.  
Table 4. Prediction of lymph node metastasis based on curettage histology and curettage specimen DNA ploidy in 568 lymph node sampled 
patients with endometrial cancer FIGO stage I, II or III in the MoMaTEC* multicentre trial. Univariate and multivariate odds ratios (OR) by 
logistic regression. 
 
Variable n Univariate OR 95% CI P Multivariate OR 95% CI P 
Curettage histology classificationa        
Low-risk 441 1   1   
High-risk 127 3.04 1.76-5.24 <0.001 2.23 1.20-4.13 0.011 
        
Curettage DNA ploidyb        
Diploid 412 1   1   
Non-diploid 156 2.73 1.60-4.66 <0.001 1.94 1.06-3.55 0.033 
        
 
aCurettage histology classified as low-risk (benign, hyperplasia or endometrioid grade 1-2) and high risk (non-endometrioid or endometrioid 
grade 3). bNon-diploid classification comprising aneuploid, tetraploid and polyploid curettage. *Molecular Markers in Treatment of Endometrial 
Cancer 
Table 5. Disease specific survival for 733 endometrial cancer patients related to 
clinicopathological variables and curettage specimen DNA ploidy. All p-values by Kaplan-Meier 
survival analysis with log-rank significance test.  
 
Variable n Number of deaths 5-year survival P 
     
Age     
<66 360 21 93.0%  
≥66 373 56 77.0% <0.001 
     
Information available preoperatively   
Curettage histologya     
Low-risk 569 34 91.3%  
High-risk 161 43 62.4% <0.001 
     
Curettage DNA ploidyb     
Diploid 529 38 89.6%  
Non-Diploid 204 39 74.4% <0.001 
     
Information available postoperatively   
FIGO Stage     
I-II 623 29 93.3%  
III-IV 110 48 38.0% <0.001 
     
Myometrial infiltrationc     
<50% 429 17 94.4%  
≥50% 227 37 76.8% <0.001 
     
 Histological type     
Endometrioid 618 37 91.3%  
Non-endometrioid 115 40 52.7% <0.001 
     
Histological graded     
Grades 1-2 517 25 93.0%  
Grad 3 214 52 67.4% <0.001 
     
Lymph node metastasise     
Negative 485 22 93.7%  
Positive 66 20 55.7% <0.001 
     
     
 
aCurettage histological risk classification as either low risk (benign, hyperplasia or endometrioid 
grade 1-2) or high risk (comprising non-endometrioid or endometrioid grade 3 histology). 
Information is missing for 3 patients. bNon-diploid curettage status includes aneuploid, tetraploid 
and polyploidy samples. cMyometrial infiltration missing for 77 patients. dHistological grade 
missing for 2 patients. eLymph node metastasis evaluated in 551 patients with follow-up 
information.  
